Seems like news days have gotten slower with all snow on the Right coast USA - maybe Washington & NYC are directing some of that hot air toward snow melt.
Scrips News reports that Sanofi-Aventis flu vaccine sales exceeded 1 billion Euros in the 4th Qtr, and resulted in a 10% increase in net income. This is a 55% increase over prior year in their human vaccine unit sales.
Despite this, Fierce Pharma's recap of a WSJ article pointed out some pothole potential in the Sanofi earnings report as earnings did benefit from a change in both tax policy and accounting reporting rules. Further, Sanofi is facing generic competition and has also acquired generics themselves which will provide downward pressure on margins.
Fierce Biotech reports that Genzyme could be facing stiff competition from rivals Shire Pharmaceuticals and Protalix as both report promising clinical results with drugs to treat Gaucher's disease. This is estimated to be a $1.2 billion market for Genzyme and analysts are predicting that up to 1/3 market share could be lost to its rivals.
Posted by Bruce Lehr Feb 12, 2010
Comments